ELVN - Company ID 0001672619
The table below shows Enliven Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $29.00M | $20.69M | $18.23M | $21.49M | $24.89M | $21.26M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.21M |
| $7.14M |
| $6.87M |
| $7.09M |
| $6.80M |
| $5.81M |
| Operating income | -$37.21M | -$27.82M | -$25.10M | -$28.58M | -$31.69M | -$27.07M |
| Income tax | - | - | $0.00 | $0.00 | - | $0.00 |
| Net income | -$32.48M | -$23.63M | -$20.15M | -$25.34M | -$28.54M | -$23.16M |
| EPS (diluted) | -$0.49 | -$0.38 | -$0.32 | -$0.49 | -$0.57 | -$0.48 |